Skip to content

BioNTech Says Covid Vaccine Revenue May Be Lower This Year

Updated on

BioNTech SE said its revenue from the Covid-19 shot it sells together with Pfizer Inc. may be lower this year than last, predicting sales between 13 billion euros and 17 billion euros ($14.7 billion and $19.3 billion). 

The company said Covid vaccine sales last year will total 16 billion euros to 17 billion euros. It issued the 2022 prediction in an investor presentation on Tuesday and is due to release fourth-quarter financial data on March 30.